Prot# S1103: A Phase I, Open-Label, Non-Randomized, Dose-Finding, Safety, Tolerance, and Pharmacokinetic Study of Orally Administered S-1 in Combination with Gemcitabine and Erlotinib in Patients with Advanced Solid Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date7/1/09 → 7/1/13

Funding

  • Taiho Pharma U.S.A., Inc. (S1103)